Abel Hall LLC
NVO icon

Abel Hall LLC’s Novo Nordisk NVO Stock Holding History

Abel Hall LLC’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$639K Sell
16,866
-2,332
-12% -$108K 0.12% 150
2026
Q2 		$920K Buy
19,198
+13,124
+216% +$564K 0.16% 94
2026
Q1 		$223K Sell
6,074
-8,778
-59% -$416K 0.05% 561
2025
Q4 		$756K Buy
14,852
+6,923
+87% +$354K 0.18% 90
2025
Q3 		$440K Buy
7,929
+1,724
+28% +$101K 0.18% 110
2025
Q2 		$428K Buy
6,205
+1,184
+24% +$80.5K 0.2% 105
2025
Q1 		$349K Sell
5,021
-992
-16% -$81.9K 0.21% 84
2024
Q4 		$517K Buy
6,013
+206
+4% +$22.3K 0.33% 43
2024
Q3 		$691K Buy
5,807
+162
+3% +$21.6K 0.45% 33
2024
Q2 		$806K Buy
5,645
+388
+7% +$51.4K 0.57% 30
2024
Q1 		$675K Buy
5,257
+212
+4% +$25.2K 0.51% 32
2023
Q4 		$522K Buy
+5,045
New +$499K 0.45% 35

Other funds holding NVO

Saratoga Research & Investment Management
Saratoga Research & Investment Management Saratoga, California $1.82B AUM 11.8% 1-Year Est. Return
Oppenheimer Asset Management
Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return
Euro Pacific Asset Management
Euro Pacific Asset Management Dorado, Puerto Rico $1.22B AUM 22.48% 1-Year Est. Return
Nichols & Pratt Advisers
Nichols & Pratt Advisers Boston, Massachusetts $1.68B AUM 20.22% 1-Year Est. Return
Corda Investment Management
Corda Investment Management Houston, Texas $1.52B AUM 30.53% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
Philip James Wealth Mangement
Philip James Wealth Mangement Milton, Georgia $906M AUM 30.39% 1-Year Est. Return
QV Investors
QV Investors Calgary, Alberta, Canada $1.36B AUM 20.86% 1-Year Est. Return
Cantor Fitzgerald Investment Advisors
Cantor Fitzgerald Investment Advisors New York $1.81B AUM 23.74% 1-Year Est. Return
Penbrook Management
Penbrook Management New York $169M AUM 32.52% 1-Year Est. Return

Abel Hall LLC's NVO Position: Q3 2026 in Review

Abel Hall LLC reduced its Novo Nordisk (NVO) stake by 12% in Q3 2026, selling an estimated $108K and leaving 16,866 shares worth $639K. The position accounts for 0.12% of the portfolio, ranked #150.

Abel Hall LLC first reported a position in NVO in Q4 2023 and has held it in 12 quarters since. The position peaked at $920K in Q2 2026. 402 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Abel Hall LLC held 16,866 shares of Novo Nordisk worth $639K as of Q3 2026.
  • Abel Hall LLC sold 2,332 Novo Nordisk shares in Q3 2026, an estimated $108K.
  • Novo Nordisk made up 0.12% of Abel Hall LLC's portfolio in Q3 2026, its #150 holding.
  • Abel Hall LLC first reported a position in Novo Nordisk in Q4 2023 and has held it in 12 quarters since.
  • Abel Hall LLC's Novo Nordisk position peaked at $920K in Q2 2026.
  • 402 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.